Tryptamine Therapeutics (AU:TYP) has released an update.
Tryptamine Therapeutics, a clinical-stage biotech company, has announced the release of documents pertaining to its 2024 AGM, highlighting its advances in psychotherapeutic treatments using psilocin. The company has reported significant progress with its TRP-8803 program, demonstrating over 80% reduction in binge eating episodes and is expanding its clinical trials to address other conditions like fibromyalgia and irritable bowel syndrome.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.